<DOC>
	<DOCNO>NCT03031496</DOCNO>
	<brief_summary>The combination diuretic amiloride hydrochloride ( HCl ) hydrochlorothiazide ( HCTZ ) ( GSK3542503 ) indicate treatment hypertension , congestive heart failure hepatic cirrhosis ascites edema . This first time human ( FTIH ) study aim determine whether test product GSK3542503 bioequivalent reference ( ref ) hydrochlorothiazide 50 milligram ( mg ) /amiloride hydrochlorothiazide 5 mg healthy adult participant fast condition base pharmacokinetic ( PK ) endpoints . This phase I , open label , balance , randomize , single dose , two-way crossover study , enrol approximately 42 healthy participant single center . Study participant randomize one two treatment sequence ( A-B B-A ) accordance randomization schedule . A single dose one two treatment A ( Test : GSK3542503 , hydrochlorothiazide 50 mg amiloride hydrochloride 5 mg fix dose combination ) B ( Reference : Moduretic , hydrochlorothiazide 50 mg amiloride hydrochloride 5 mg fix dose combination ) , administer Day 1 , treatment period . Each participant participate treatment period receive single dose treatment . The treatment period separate washout period least 7 day 14 day . The total duration study participant expect 5 7 week , screen last visit . A maximum 42 participant randomize least 32 evaluable participant complete study .</brief_summary>
	<brief_title>Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg : 5 mg Tablets Reference Product Healthy Adult Participants Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amiloride , hydrochlorothiazide drug combination</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>Participants must between18 65 year age inclusive , time signing informed consent . Healthy , nonsmoker , determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test , cardiac monitoring . A participant clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside normal reference range population study may include investigator consultation medical monitor require , agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 1930 kg/meter^2 ( inclusive ) . Healthy male female participant Male participant must agree use contraception 3 day dose study treatment refrain donate sperm period . A female participant eligible participate pregnant , breastfeeding , least one follow condition applies : woman childbearing potential ( WOCBP ) , WOCBP agree follow contraceptive guidance treatment period least 30 day last dose study treatment . The investigator responsible ensure male female study participant understand correctly use method contraception . Capable give sign informed consent , include compliance requirement restriction . History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study treatment ; interfere interpretation data . Abnormal renal function measure creatinine clearance . Presence hyperkalemia serum potassium great upper limit normal ( ULN ) . History know acute angle closure glaucoma ocular complaint , could increase risk ophthalmic reaction deem investigator . Abnormal BP determine investigator . Alanine transaminase ( ALT ) &gt; 1.5 time ULN . Bilirubin &gt; 1.5 time ULN ( isolated bilirubin &gt; 1.5 time ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percentage ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT interval correct heart rate accord Bazett 's formula ( QTcB ) &gt; 450 millisecond ( msec ) . For purpose data analysis , QTcB , use . Past intend use overthecounter prescription medication include herbal medication , within 14 day prior dose . Specific medication list protocol study may allow . Where participation study would result loss blood blood product excess 500 milliliter ( mL ) within 90 day . Exposure 4 new chemical entity within 12 month prior first dose day . Current enrolment past participation within last 90 day sign consent clinical study involve investigational study treatment . Presence hepatitis B surface antigen ( HBsAg ) screening , positive hepatitis C antibody test result screen . Participants positive hepatitis C antibody due prior resolve disease enrol , confirmatory negative hepatitis C ribonucleic acid ( RNA ) test obtain . Positive prestudy drug/alcohol screen . Positive human immunodeficiency virus ( HIV ) antibody test . Regular use know drug abuse . Sensitivity heparin heparininduced thrombocytopenia . Sensitivity study treatment , component thereof , drug allergy include allergy penicillin sulfonamide , opinion investigator medical monitor , contraindicate participation study . Regular alcohol consumption within 6 month prior study defined average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Participants risk define protocol study exclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cross-over</keyword>
	<keyword>Hydrochlorothiazide</keyword>
	<keyword>Amiloride hydrochloride</keyword>
	<keyword>Phase I</keyword>
	<keyword>GSK3542503</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>FTIH</keyword>
</DOC>